Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth

Published version of a preprint

Abstract

Most colorectal cancers (CRC) are initiated by mutations of APC, leading to increased β-catenin–mediated signaling. However, continued requirement of Wnt/β-catenin signaling for tumor progression in the context of acquired KRAS and other mutations is less well-established. To attenuate Wnt/β-catenin signaling in tumors, we have developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β-catenin destabilization. We show that novel tankyrase inhibitors completely block ligand-driven Wnt/β-catenin signaling in cell culture and display approximately 50% inhibition of APC mutation–driven signaling in most CRC cell lines. It was previously unknown whether the level of AXIN protein stabilization by tankyrase inhibition is sufficient to impact tumor growth in the absence of normal APC activity. Compound G007-LK displays favorable pharmacokinetic properties and inhibits in vivo tumor growth in a subset of APC-mutant CRC xenograft models. In the xenograft model most sensitive to tankyrase inhibitor, COLO-320DM, G007-LK inhibits cell-cycle progression, reduces colony formation, and induces differentiation, suggesting that β-catenin–dependent maintenance of an undifferentiated state may be blocked by tankyrase inhibition. The full potential of the antitumor activity of G007-LK may be limited by intestinal toxicity associated with inhibition of Wnt/β-catenin signaling and cell proliferation in intestinal crypts. These results establish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutant CRC models and uncover potential diagnostic and safety concerns to be overcome as tankyrase inhibitors are advanced into the clinic. Cancer Res; 73(10); 3132–44. ©2013 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-4562

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

See all 342

Metadata

Authors
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., Machon, O., Korinek, V., Choo, E., Diaz, D., Merchant, M., Polakis, P., Holsworth, D. D., Krauss, S., & Costa, M.
Affiliations
  • Oslo University Hospital (NO)
  • Authors' Affiliations: Departments of 1Cancer Targets, 2Translational Oncology, 3Drug Metabolism and Pharmacokinetics, 4Biochemical and Cellular Pharmacology, 5Discovery Chemistry, 6Pharmaceutical Sciences, 7Safety Assessment, and 8Pathology, Genentech, Inc., South San Francisco, California; 9SFI-CAST Biomedical Innovation Center, Unit for Cell Signaling, Oslo University Hospital, Forskningsparken; 10ODIN Therapeutics AS, Forskningsparken, Oslo, Norway; and 11Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
Corresponding author
Costa, Mike
Venue
Cancer Research
Published
2013-05-12
Volume
73
Issue
10
Pages
3132-3144
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2105240743
Cited by
316
References
46
Citations by year
2026: 11 · 2025: 21 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 39 · 2020: 34 · 2019: 27 · 2018: 23 · 2017: 32 · 2016: 25 · 2015: 28 · 2014: 18 · 2013: 12
FWCI
13.71
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • ASEP (submittedVersion, public-domain)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
tankyrase inhibitors, colorectal cancer, APC mutation, Wnt/β-catenin signaling, poly(ADP-ribosyl)ation, tumor growth inhibition, xenograft models, cell cycle progression, intestinal toxicity, KRAS mutation
MeSH terms
Animals, Enzyme Inhibitors, Humans, Mutation, Piperidines, Sulfones, Triazoles, Colorectal Neoplasms, Genes, APC, Spheroids, Cellular, Xenograft Model Antitumor Assays, Tankyrases, Cell Line, Tumor, Cell Proliferation, beta Catenin, Mice, Wnt Signaling Pathway, Axin Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-4562
The paper
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., Machon, O., Korinek, V., Choo, E., Diaz, D., Merchant, M., Polakis, P., Holsworth, D. D., Krauss, S., & Costa, M. (2013). A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-4562

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.